↓ Skip to main content

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

Overview of attention for article published in BMC Cancer, March 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial
Published in
BMC Cancer, March 2015
DOI 10.1186/s12885-015-1199-8
Pubmed ID
Authors

Ninos Ayez, Eric P van der Stok, Hans de Wilt, Sandra A Radema, Richard van Hillegersberg, Rudi M Roumen, Gerard Vreugdenhil, Pieter J Tanis, Cornelis J Punt, Cornelis H Dejong, Rob L Jansen, Henk M Verheul, Koert P de Jong, Geke A Hospers, Joost M Klaase, Marie-Cecile Legdeur, Esther van Meerten, Ferry A Eskens, Nelly van der Meer, Bruno van der Holt, Cornelis Verhoef, Dirk J Grünhagen

Abstract

Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate definite overall survival benefit. This may partly be due to the fact that these studies often involve strict inclusion criteria. Consequently, patients with a high risk profile as characterized by Fong's Clinical Risk Score (CRS) are often underrepresented in these studies. Conceptually, this group of patients might benefit the most from chemotherapy. The present study evaluates the impact of neo-adjuvant chemotherapy in high-risk patients with primary resectable colorectal liver metastases, without extrahepatic disease. Our hypothesis is that adding neo-adjuvant chemotherapy to surgery will provide an improvement in overall survival (OS) in patients with a high-risk profile. CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to either surgery alone (standard treatment, arm A) or to 6 cycles of neo-adjuvant oxaliplatin-based chemotherapy, followed by surgery (arm B). Patients must be ≥ 18 years of age with liver metastases of histologically confirmed primary colorectal carcinoma. Patients with extrahepatic metastases are excluded. Liver metastases must be deemed primarily resectable. Only patients with a CRS of 3-5 are eligible. The primary study endpoint is OS. Secondary endpoints are progression free survival (PFS), quality of life, morbidity of resection, treatment response on neo-adjuvant chemotherapy, and whether CEA levels can predict treatment response. CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer to the question if adding neo-adjuvant chemotherapy to surgery will improve OS in a well-defined high-risk patient group with colorectal liver metastases. The CHARISMA is registered at European Union Clinical Trials Register (EudraCT), number: 2013-004952-39 , and in the "Netherlands national Trial Register (NTR), number: 4893.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 1%
Unknown 79 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 18%
Student > Master 9 11%
Researcher 9 11%
Other 5 6%
Student > Bachelor 3 4%
Other 7 9%
Unknown 33 41%
Readers by discipline Count As %
Medicine and Dentistry 33 41%
Nursing and Health Professions 3 4%
Biochemistry, Genetics and Molecular Biology 2 3%
Unspecified 1 1%
Arts and Humanities 1 1%
Other 3 4%
Unknown 37 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2023.
All research outputs
#14,646,748
of 24,960,237 outputs
Outputs from BMC Cancer
#3,150
of 8,828 outputs
Outputs of similar age
#130,455
of 268,879 outputs
Outputs of similar age from BMC Cancer
#84
of 244 outputs
Altmetric has tracked 24,960,237 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,828 research outputs from this source. They receive a mean Attention Score of 4.6. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,879 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 244 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.